- Home
- GRNT vs CGEM Comparison
GRNT vs CGEM Comparison
Compare GRNT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRNT | CGEM |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.8M | 904.7M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GRNT | CGEM |
|---|---|---|
| Price | $5.55 | $13.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $6.00 | ★ $30.13 |
| AVG Volume (30 Days) | 842.3K | ★ 881.8K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.36% | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $450,306,000.00 | N/A |
| Revenue This Year | $18.12 | N/A |
| Revenue Next Year | $13.12 | $5.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.49 | N/A |
| 52 Week Low | $4.18 | $5.68 |
| 52 Week High | $6.59 | $16.74 |
Technical Indicators
Market Signals| Indicator | GRNT | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 42.75 |
| Support Level | $4.94 | $12.41 |
| Resistance Level | $5.98 | $16.21 |
| Average True Range (ATR) | 0.23 | 0.94 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 55.07 | 11.57 |
Price Performance
Historical ComparisonAbout GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.